Budapest Retina Associates
- Address
- lock Available on a paid plan
Eye Diseases and Ocular Physiology
At Budapest Retina Associates, clinical research focuses on eye diseases and the function of the retina, with studies centered on conditions that affect central vision and macular health. The trials are designed to assess whether new or improved treatments can better preserve sight and support eye health in people with retinal swelling.
- Diabetic Macular Edema is being studied to improve treatment options for vision loss related to diabetes.
- Ocular physiological phenomena are examined to better understand how the eye responds to therapy and disease.
- Research also includes macular edema secondary to retinal vein occlusion, with a focus on treatment effectiveness and safety.
Overall, the site is contributing to clinical research that evaluates how well different eye treatments work and whether they can offer meaningful benefits for patients with retinal swelling and reduced vision.
Retinal Swelling and Vision Treatment Studies
Clinical trials at this hospital/clinic in Budapest are aimed at improving care for people with diabetic macular edema and macular edema secondary to retinal vein occlusion. The research compares treatment approaches to see which options may provide better vision outcomes while maintaining safety.
- Studies in diabetic macular edema are evaluating new eye-drop and treatment strategies for effectiveness.
- Research in retinal vein occlusion focuses on whether a stronger treatment approach can improve visual acuity.
- The trials aim to support better management of macular edema through more effective and practical therapies.
This research landscape reflects a strong interest in refining therapies for retinal disease, with attention to both visual improvement and patient safety.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG2active
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Viridian Therapeutics Inc.4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Budapest Retina Associates
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aflibercept | 7 | Unknown | 2023-09-13 | 2026-05-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.